Key Points
- IDEXX Laboratories Director Lawrence Kingsley sold 2,203 shares at an average price of $532.08, generating $1.17 million and reducing his holdings by 18.72% to 9,568 shares.
- IDXX shares opened at $515.15, near their 12-month low of $511.16, and were trading below both their 50-day and 200-day moving averages.
- The company exceeded quarterly expectations with $4.27 in EPS and $1.22 billion in revenue, while analysts maintained a “Moderate Buy” consensus and an average price target of $747.
IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) Director Lawrence Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares of the company's stock, valued at $5,090,941.44. This represents a 18.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
IDEXX Laboratories Trading Down 1.0%
NASDAQ:IDXX opened at $515.15 on Thursday. IDEXX Laboratories, Inc. has a 12 month low of $511.16 and a 12 month high of $769.98. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $40.58 billion, a price-to-earnings ratio of 36.23, a PEG ratio of 2.78 and a beta of 1.54. The firm has a fifty day simple moving average of $557.68 and a two-hundred day simple moving average of $567.79.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business's revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have recently commented on IDXX. Citigroup boosted their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a report on Wednesday, August 5th. Weiss Ratings cut IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a report on Thursday, August 27th. UBS Group increased their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. Barclays reduced their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a research report on Tuesday, August 11th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $747.00.
Read Our Latest Research Report on IDEXX Laboratories
Institutional Trading of IDEXX Laboratories
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SHP Wealth Management purchased a new stake in shares of IDEXX Laboratories in the fourth quarter worth approximately $26,000. Virtus Advisers LLC purchased a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $26,000. J.Safra Asset Management Corp bought a new stake in IDEXX Laboratories during the second quarter worth $25,000. Elevation Wealth Partners LLC grew its holdings in IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock worth $26,000 after buying an additional 32 shares in the last quarter. Finally, Wormser Freres Gestion raised its position in IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company's stock valued at $37,000 after buying an additional 47 shares during the last quarter. 87.84% of the stock is owned by institutional investors.
IDEXX Laboratories Company Profile
(
Get Free Report)
IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.
Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
